Vishakha Singh

Dedicated professional with a robust background in health relations, operations management, and biomedical research. Experienced in fostering collaborative research partnerships within the healthcare sector, with a focus on trends analysis and adoption strategies for innovative health technologies. Proven track record in leading clinical trials, molecular lab operations, and executing research projects in neurobiology and metabolic regulation. Seeking to leverage expertise in a dynamic role that combines scientific inquiry with strategic health management

• Class 9th and 10th - Science and Math (2019-2021)
• Class 11th, 12th, and Medical Entrance Exams - Biology (2019-2021)
• Bachelor of Sciences (2021-2022)
• Life Sciences study batch for national competitive entrance exams (2021-2022)

• Healthcare Leadership Award: World Health & Wellness Congress, Mumbai - Feb 16, 2023.
• Most Iconic Healthcare Leaders (Global) Award: World Health & Wellness Congress, Mumbai - Feb 16, 2024.

• Do ANGPTL-4 and galectin-3 reflect the severity of coronary artery disease, https://www.ncbi.nlm.nih.gov/pubmed/28795637
• Loss of neuroligin in rat mice impacting the development of glial cells in the hippocampus of rat brain, Manuscript for publication

1)Using sleep as a biomarker for disease prognosis and prevention using AI platform: I am the Lead Manager in Health Relations at Neurobit Innovations. Primarily responsible for developing and establishing collaborative research relationships with healthcare and health technology companies across India. My objectives include studying trends in the healthcare market and adoption strategies of new innovations.

 My work involved: ● Establishing links and relations with scientists and doctors. ● Branding Neurobit at Conferences. Active conference participation. ● Business strategy and development. Active reach-out and meetings for the same. ● Studying healthcare and innovation market. ● Designing assets at Neurobit for new projects.

2)Inhibitory control and reward sensitivity in obese adolescents and adults, fMRI study and co-related neuroinflammatory marker: Obesity is a metabolic condition that leads to comorbidities like diabetes, systemic inflammation,cardiomyopathies, and cognitive impairment. We aim at finding the systemic biomarkers equally contributing to obesity and neuro-inflammation with the help of neuro-imaging tests like fMRI and blood biomarkers with the help of ELISA.

3)Beta Thalassemia Clinical Study Trial:Working with a NGO named Sankalp, I was involved in setting up the molecular lab and developing assays with a short turnover time. Assay designing included assays for mutation studies, viral studies pre and post-bone marrow transplant in beta-thalassemia patients, and chimerism studies.

4)Mapping the MetabolicRegulation of skeletal muscle atrophy in mice: The field of muscle myopathies lacks a well-characterized and reproducible model to understand disease regulation. To understand the metabolic signatures regulating muscle atrophy at the transcriptional and translational levels, I developed disuse induced skeletal muscle atrophy model in mice. The model developed was robust and reproducible which was used for characterization of metabolic markers causing atrophy using qPCR, immunohistochemistry, and immunofluorescence with confocal microscopy. The metabolic changes showed dysregulation of lipid metabolic pathways which sustained and caused the atrophy to develop in skeletal muscle. Further metabolic studies were aimed to understand the complete metabolome of atrophic tissue with the help of mass spectrometry. Interrogating the gateway causing metabolic differences to set in will help in finding interventions that can be involved in rescuing skeletal muscle atrophy. The project was carried under the guidance of Dr. Arvind Ramanathan, RCF, InStem, Bangalore.

6)Evaluation Of Novel Biomarker in Acute Coronary Syndrome: It was a clinical trial study conducted on patients afflicted with coronary artery disease. Galectin-3 and ANGPTL-4 were seen to have a co-relation with coronary disorders. The project aimed to interrogate if the level of Galectin-3 and ANGPTL-4 in the blood serum of patients can be used as a biomarker of coronary artery disorder and its severity. The project was guided by Dr. Melvin George from SRM Medical College and Research Centre, Chennai.